Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVAX-1
- Development stage
- Preclinical
- Lead developer
- University of California, Irvine
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
IVAX-1 is a nanoparticulate combination vaccine adjuvant system developed by researchers at the University of California, Irvine. It is formulated as a squalene oil-in-water nanoemulsion (AddaVax) that incorporates two synergistic Toll-like receptor (TLR) agonists: the TLR4 agonist monophosphoryl lipid A (MPLA) and the TLR9 agonist CpG oligodeoxynucleotide (ODN) 1018. By activating multiple innate immune pathways simultaneously, IVAX-1 enhances dendritic cell maturation and recruitment of myeloid cells to the injection site, promoting robust, long-lasting cell-mediated (Th1-biased) and humoral immune responses. Preclinical studies have demonstrated that IVAX-1-adjuvanted vaccines provide superior protection and viral clearance against respiratory pathogens, such as H5N1 influenza and Chlamydia trachomatis, as well as efficacy in melanoma tumor models.
- Other names
- MPLA + CpG 1018 + AddaVax
02
Targets
MYD88 (Myeloid differentiation primary response protein MyD88)NF-κBTLR9 (Toll-like receptor 9)TRIF (TIR-domain-containing adapter-inducing interferon-beta)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on IVAX-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IVAX-1.